Filing Flows › Cytek Biosciences (CTKB) › Guidance history
Cytek Biosciences (CTKB) guidance history: what it guided and what it reported
Cytek Biosciences gave guidance in 3 earnings releases on file since May 7, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $205M–$212M (May 7, 2026) → raised $207M–$212M (Aug 5, 2026) → reaffirmed $208M–$211M (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Questions
Does Cytek Biosciences beat its guidance?
Cytek Biosciences gave guidance in 3 earnings releases on file since May 7, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.